000 | 01984 a2200565 4500 | ||
---|---|---|---|
005 | 20250515092308.0 | ||
264 | 0 | _c20071120 | |
008 | 200711s 0 0 eng d | ||
022 | _a0003-9926 | ||
024 | 7 |
_a10.1001/archinte.167.19.2054 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aReynolds, Harmony R | |
245 | 0 | 0 |
_aImpact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. _h[electronic resource] |
260 |
_bArchives of internal medicine _cOct 2007 |
||
300 |
_a2054-60 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAbciximab |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
650 | 0 | 4 | _aChi-Square Distribution |
650 | 0 | 4 | _aCoronary Angiography |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFibrinolytic Agents _xadverse effects |
650 | 0 | 4 |
_aHemorrhage _xepidemiology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadverse effects |
650 | 0 | 4 | _aInfusions, Intravenous |
650 | 0 | 4 | _aLogistic Models |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMyocardial Infarction _xcomplications |
650 | 0 | 4 | _aMyocardial Revascularization |
650 | 0 | 4 |
_aRecombinant Proteins _xadverse effects |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aSex Factors |
650 | 0 | 4 | _aStatistics, Nonparametric |
650 | 0 | 4 |
_aStroke _xepidemiology |
650 | 0 | 4 |
_aTissue Plasminogen Activator _xadverse effects |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aFarkouh, Michael E | |
700 | 1 | _aLincoff, A Michael | |
700 | 1 | _aHsu, Amy | |
700 | 1 | _aSwahn, Eva | |
700 | 1 | _aSadowski, Zygmunt P | |
700 | 1 | _aWhite, Jennifer A | |
700 | 1 | _aTopol, Eric J | |
700 | 1 | _aHochman, Judith S | |
773 | 0 |
_tArchives of internal medicine _gvol. 167 _gno. 19 _gp. 2054-60 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1001/archinte.167.19.2054 _zAvailable from publisher's website |
999 |
_c17474504 _d17474504 |